Aspire BioPharma Net Income
| ASBP Stock | 1.69 0.44 20.66% |
As of the 2nd of February, Aspire BioPharma shows the Mean Deviation of 8.62, standard deviation of 12.87, and Risk Adjusted Performance of (0.10). Aspire BioPharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Analyzing historical trends in various income statement and balance sheet accounts from Aspire BioPharma's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Aspire BioPharma's valuation are summarized below:Gross Profit | Market Capitalization | Enterprise Value Revenue 6.4 K | Revenue | Earnings Share (37.43) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -1.2 M | -1.1 M | |
| Net Loss | -11.3 M | -10.7 M | |
| Net Loss | (0.44) | (0.42) |
Aspire | Net Income | Build AI portfolio with Aspire Stock |
Evaluating Aspire BioPharma's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Aspire BioPharma's fundamental strength.
Latest Aspire BioPharma's Net Income Growth Pattern
Below is the plot of the Net Income of Aspire BioPharma over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Aspire BioPharma financial statement analysis. It represents the amount of money remaining after all of Aspire BioPharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Aspire BioPharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aspire BioPharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (1.31 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Aspire Net Income Regression Statistics
| Arithmetic Mean | (1,590,655) | |
| Coefficient Of Variation | (309.37) | |
| Mean Deviation | 3,502,055 | |
| Median | (25,475) | |
| Standard Deviation | 4,921,043 | |
| Sample Variance | 24.2T | |
| Range | 17M | |
| R-Value | (0.51) | |
| Mean Square Error | 19.1T | |
| R-Squared | 0.26 | |
| Significance | 0.04 | |
| Slope | (498,809) | |
| Total Sum of Squares | 387.5T |
Aspire Net Income History
Other Fundumenentals of Aspire BioPharma
Aspire Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Aspire BioPharma is extremely important. It helps to project a fair market value of Aspire Stock properly, considering its historical fundamentals such as Net Income. Since Aspire BioPharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Aspire BioPharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Aspire BioPharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Can Pharmaceuticals industry sustain growth momentum? Does Aspire have expansion opportunities? Factors like these will boost the valuation of Aspire BioPharma. If investors know Aspire will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Aspire BioPharma demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Aspire BioPharma's market price often diverges from its book value, the accounting figure shown on Aspire's balance sheet. Smart investors calculate Aspire BioPharma's intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Since Aspire BioPharma's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Aspire BioPharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Aspire BioPharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Aspire BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Aspire BioPharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Aspire BioPharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Aspire BioPharma.
| 11/04/2025 |
| 02/02/2026 |
If you would invest 0.00 in Aspire BioPharma on November 4, 2025 and sell it all today you would earn a total of 0.00 from holding Aspire BioPharma or generate 0.0% return on investment in Aspire BioPharma over 90 days. Aspire BioPharma is related to or competes with AleAnna. Aspire BioPharma is entity of United States More
Aspire BioPharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Aspire BioPharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Aspire BioPharma upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.16) | |||
| Maximum Drawdown | 63.79 | |||
| Value At Risk | (23.85) | |||
| Potential Upside | 22.58 |
Aspire BioPharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aspire BioPharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Aspire BioPharma's standard deviation. In reality, there are many statistical measures that can use Aspire BioPharma historical prices to predict the future Aspire BioPharma's volatility.| Risk Adjusted Performance | (0.10) | |||
| Jensen Alpha | (1.97) | |||
| Total Risk Alpha | (2.63) | |||
| Treynor Ratio | 1.6 |
Aspire BioPharma February 2, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.10) | |||
| Market Risk Adjusted Performance | 1.61 | |||
| Mean Deviation | 8.62 | |||
| Coefficient Of Variation | (643.01) | |||
| Standard Deviation | 12.87 | |||
| Variance | 165.54 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (1.97) | |||
| Total Risk Alpha | (2.63) | |||
| Treynor Ratio | 1.6 | |||
| Maximum Drawdown | 63.79 | |||
| Value At Risk | (23.85) | |||
| Potential Upside | 22.58 | |||
| Skewness | 0.9091 | |||
| Kurtosis | 3.28 |
Aspire BioPharma Backtested Returns
Aspire BioPharma secures Sharpe Ratio (or Efficiency) of -0.18, which signifies that the company had a -0.18 % return per unit of risk over the last 3 months. Aspire BioPharma exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Aspire BioPharma's Risk Adjusted Performance of (0.10), mean deviation of 8.62, and Standard Deviation of 12.87 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of -1.26, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Aspire BioPharma are expected to decrease by larger amounts. On the other hand, during market turmoil, Aspire BioPharma is expected to outperform it. At this point, Aspire BioPharma has a negative expected return of -2.23%. Please make sure to confirm Aspire BioPharma's potential upside, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Aspire BioPharma performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.25 |
Poor predictability
Aspire BioPharma has poor predictability. Overlapping area represents the amount of predictability between Aspire BioPharma time series from 4th of November 2025 to 19th of December 2025 and 19th of December 2025 to 2nd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Aspire BioPharma price movement. The serial correlation of 0.25 indicates that over 25.0% of current Aspire BioPharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.25 | |
| Spearman Rank Test | 0.36 | |
| Residual Average | 0.0 | |
| Price Variance | 1.82 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Aspire BioPharma reported net income of (1.31 Million). This is 100.38% lower than that of the Pharmaceuticals sector and 101.87% lower than that of the Health Care industry. The net income for all United States stocks is 100.23% higher than that of the company.
Aspire Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aspire BioPharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aspire BioPharma could also be used in its relative valuation, which is a method of valuing Aspire BioPharma by comparing valuation metrics of similar companies.Aspire BioPharma is currently under evaluation in net income category among its peers.
Aspire Fundamentals
| Return On Asset | -1.95 | ||||
| Operating Margin | (590.16) % | ||||
| Current Valuation | 12.52 M | ||||
| Shares Outstanding | 4 M | ||||
| Shares Owned By Insiders | 10.84 % | ||||
| Shares Owned By Institutions | 3.99 % | ||||
| Number Of Shares Shorted | 29.17 M | ||||
| Price To Sales | 4,389 X | ||||
| Gross Profit | 884 | ||||
| EBITDA | (11.65 M) | ||||
| Net Income | (1.31 M) | ||||
| Total Debt | 1.27 M | ||||
| Book Value Per Share | (9.26) X | ||||
| Cash Flow From Operations | (265.19 K) | ||||
| Short Ratio | 0.61 X | ||||
| Earnings Per Share | (37.43) X | ||||
| Beta | 0.82 | ||||
| Market Capitalization | 8.52 M | ||||
| Total Asset | 147.99 K | ||||
| Retained Earnings | (2.78 M) | ||||
| Working Capital | (1.54 M) | ||||
| Net Asset | 147.99 K |
About Aspire BioPharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aspire BioPharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aspire BioPharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aspire BioPharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Aspire BioPharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aspire BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aspire BioPharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Aspire Stock
Moving against Aspire Stock
| 0.79 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
| 0.79 | PFE | Pfizer Inc Earnings Call Tomorrow | PairCorr |
| 0.79 | DD | Dupont De Nemours Earnings Call This Week | PairCorr |
| 0.77 | MRK | Merck Company Earnings Call Tomorrow | PairCorr |
| 0.65 | CSCO | Cisco Systems Sell-off Trend | PairCorr |
The ability to find closely correlated positions to Aspire BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aspire BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aspire BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aspire BioPharma to buy it.
The correlation of Aspire BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aspire BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aspire BioPharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aspire BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Aspire Stock Analysis
When running Aspire BioPharma's price analysis, check to measure Aspire BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aspire BioPharma is operating at the current time. Most of Aspire BioPharma's value examination focuses on studying past and present price action to predict the probability of Aspire BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aspire BioPharma's price. Additionally, you may evaluate how the addition of Aspire BioPharma to your portfolios can decrease your overall portfolio volatility.